{"id":"W4379282910","doi":"10.1200/jco.2023.41.16_suppl.3089","title":"Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Theratechnologies (Canada)","funders":"","keywords":"Medicine; Docetaxel; Tolerability; Pharmacokinetics; Oncology; Adverse effect; Internal medicine; Drug; Pharmacology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007857333,0.0005829714,0.0008232233,0.0002663732,0.0001944809,0.0004934111,0.0003337363,0.0006089297,0.001455207],"category_scores_gemma":[0.0003429433,0.0002643049,0.0004907318,0.0002934419,0.0004334652,0.0005187233,0.0002031655,0.001631373,0.0003857441],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006902987,"about_ca_system_score_gemma":0.0006755769,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000658905,"about_ca_topic_score_gemma":0.001570588,"domain_scores_codex":[0.9998164,0.00008497573,0.00001092286,0.00002993267,0.00002411566,0.00003376528],"domain_scores_gemma":[0.9997132,0.00005464201,0.00007529194,0.00002021537,0.00001917394,0.0001173267],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3170227,0.06647885,0.02058521,0.001049154,0.001051837,0.0008525305,0.0006932095,0.005986597,0.3932704,0.000445206,0.0062417,0.1863226],"study_design_scores_gemma":[0.1792393,0.7338235,0.03092201,0.00003203459,0.0005410252,0.001189533,0.0001198496,0.002361459,0.04545955,0.0001882943,0.006080608,0.00004278444],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974937,0.0007266765,0.0002997715,0.0001605579,0.00002081493,0.0003644752,0.0004485818,0.00003337293,0.0004521319],"genre_scores_gemma":[0.9950328,0.0009215475,0.001048386,0.0002644087,0.00004737734,0.0003452833,0.00137806,0.00001653196,0.0009457034],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001455207,"threshold_uncertainty_score":0.005008459,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1753364467519187,"score_gpt":0.4953780951590365,"score_spread":0.3200416484071178,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}